Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324945 · ClinicalTrials.gov registry record · NA
Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients
A NA study, sponsored by Rachel Miller.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03324945: Completed NA study, sponsored by Rachel Miller.
NCT03324945 is a NA study that has completed, run by Rachel Miller. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03324945, a NA study, has completed, sponsored by Rachel Miller.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a spectrum of neurocognitive deficits experienced during and after the administration of chemotherapy for cancer. The incidence of CICI is significant, affecting anywhere from 25 to 75% of survivors, and the biologic basis is unknown. This novel study is designed to address the questions of incidence and biological cause for CICI, while gaining a better understanding of the structural and functional effects of chemotherapy on the brain.
Primary Outcome
To address the primary aim, RCI (which is essentially a z-score) for each patient will be calculated from the pre-, post-chemotherapy Montreal Cognitive Assessment (MoCA) test results. Then a Wilcoxon signed rank test will be applied to the RCI values with corresponding 95% confidence intervals.
Interventions
- BEHAVIORAL Neurocognitive assessments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2019-04-01 |
| Phase | NA |
What the finished NCT03324945 record still lists
NCT03324945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Neurocognitive assessments is the first listed.
NCT03324945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03324945 about?
NCT03324945 is a clinical study titled "Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients". Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a spectrum of neurocognitive deficits experienced during and after the administration of chemotherapy for cancer. The incidence of CICI is significant, affecting anywhere from 25 to 75% of survivors, and the biologic ba...
What is the current status of trial NCT03324945?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2016-08-01. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03324945?
The interventions under investigation include: Neurocognitive assessments (BEHAVIORAL).
Who is sponsoring clinical trial NCT03324945?
This trial is sponsored by Rachel Miller, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03324945's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy